Southeast Asset Advisors LLC Sells 7,935 Shares of Revvity, Inc. (NYSE:RVTY)

Southeast Asset Advisors LLC reduced its position in Revvity, Inc. (NYSE:RVTY - Free Report) by 41.0% in the 4th quarter, according to its most recent filing with the SEC. The firm owned 11,413 shares of the company's stock after selling 7,935 shares during the period. Southeast Asset Advisors LLC's holdings in Revvity were worth $1,274,000 at the end of the most recent reporting period.

Several other institutional investors also recently bought and sold shares of RVTY. Invesco Ltd. grew its stake in Revvity by 18.8% during the fourth quarter. Invesco Ltd. now owns 1,740,933 shares of the company's stock worth $194,306,000 after buying an additional 274,923 shares during the period. Federated Hermes Inc. lifted its holdings in shares of Revvity by 13.7% during the 4th quarter. Federated Hermes Inc. now owns 229,524 shares of the company's stock valued at $25,617,000 after acquiring an additional 27,684 shares in the last quarter. Aster Capital Management DIFC Ltd purchased a new stake in Revvity during the 4th quarter worth $213,000. Russell Investments Group Ltd. increased its holdings in Revvity by 11.2% in the 4th quarter. Russell Investments Group Ltd. now owns 46,387 shares of the company's stock valued at $5,172,000 after purchasing an additional 4,661 shares in the last quarter. Finally, Sit Investment Associates Inc. raised its position in Revvity by 24.2% in the fourth quarter. Sit Investment Associates Inc. now owns 820 shares of the company's stock valued at $92,000 after purchasing an additional 160 shares during the period. 86.65% of the stock is currently owned by institutional investors and hedge funds.

Revvity Price Performance

NYSE RVTY traded up $1.67 on Friday, reaching $94.69. The company's stock had a trading volume of 2,420,772 shares, compared to its average volume of 886,179. The firm's 50 day moving average is $109.12 and its two-hundred day moving average is $115.17. The stock has a market cap of $11.38 billion, a PE ratio of 42.84, a PEG ratio of 3.82 and a beta of 1.07. The company has a debt-to-equity ratio of 0.41, a quick ratio of 3.03 and a current ratio of 3.60. Revvity, Inc. has a twelve month low of $89.61 and a twelve month high of $129.50.

Remove Ads

Revvity (NYSE:RVTY - Get Free Report) last issued its quarterly earnings results on Friday, January 31st. The company reported $1.42 earnings per share for the quarter, topping analysts' consensus estimates of $1.37 by $0.05. Revvity had a return on equity of 7.68% and a net margin of 9.81%. During the same period in the previous year, the company posted $1.25 EPS. As a group, sell-side analysts predict that Revvity, Inc. will post 4.94 EPS for the current year.

Revvity Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, May 9th. Investors of record on Friday, April 18th will be paid a $0.07 dividend. This represents a $0.28 annualized dividend and a yield of 0.30%. The ex-dividend date of this dividend is Thursday, April 17th. Revvity's dividend payout ratio is currently 12.67%.

Insiders Place Their Bets

In other news, insider Joel S. Goldberg sold 15,170 shares of the business's stock in a transaction on Thursday, January 30th. The shares were sold at an average price of $126.73, for a total transaction of $1,922,494.10. Following the transaction, the insider now directly owns 33,400 shares in the company, valued at $4,232,782. The trade was a 31.23 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Corporate insiders own 0.68% of the company's stock.

Analyst Ratings Changes

A number of research firms have recently issued reports on RVTY. Bank of America upgraded Revvity from a "neutral" rating to a "buy" rating and set a $138.00 target price for the company in a research note on Friday, December 13th. Sanford C. Bernstein lowered shares of Revvity from an "outperform" rating to a "market perform" rating and set a $130.00 price objective on the stock. in a research note on Friday, January 10th. KeyCorp upped their target price on shares of Revvity from $132.00 to $145.00 and gave the company an "overweight" rating in a research note on Monday, February 3rd. Barclays dropped their price target on shares of Revvity from $140.00 to $110.00 and set an "overweight" rating on the stock in a research note on Thursday. Finally, Raymond James reissued an "outperform" rating and issued a $145.00 price objective (up from $140.00) on shares of Revvity in a research report on Monday, February 3rd. Four investment analysts have rated the stock with a hold rating, eight have issued a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus target price of $133.75.

Revvity Profile

Revvity, Inc provides health sciences solutions, technologies, and services in the Americas, Europe, and Asia, and internationally. The Life Sciences segment provides instruments, reagents, informatics, software, subscriptions, detection, imaging technologies, warranties, training, and services. Its Diagnostics segment provides instruments, reagents, assay platforms, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market.